Tags

Type your tag names separated by a space and hit enter

A human monoclonal antibody blocking SARS-CoV-2 infection.
Nat Commun. 2020 05 04; 11(1):2251.NC

Abstract

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

Links

Publisher Full Text
ncbi.nlm.nih.gov
dx.doi.org
PMC Free PDF

Authors+Show Affiliations

Wang C
Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
Li W
Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
Drabek D
Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlands. Harbour BioMed, Rotterdam, the Netherlands.
Okba NMA
Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
van Haperen R
Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlands. Harbour BioMed, Rotterdam, the Netherlands.
Osterhaus ADME
University of Veterinary Medicine, Hannover, Germany.
van Kuppeveld FJM
Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
Haagmans BL
Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
Grosveld F
Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlands. Harbour BioMed, Rotterdam, the Netherlands.
Bosch BJ
Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands. b.j.bosch@uu.nl.

MeSH

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody AffinityBetacoronavirusChlorocebus aethiopsConserved SequenceCoronavirus InfectionsCross ReactionsEpitopes, B-LymphocyteHumansIn Vitro TechniquesInhibitory Concentration 50Models, MolecularPandemicsPeptidyl-Dipeptidase APneumonia, ViralProtein BindingProtein DomainsReceptors, VirusSARS VirusSpike Glycoprotein, CoronavirusVero Cells

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32366817

Citation

Wang, Chunyan, et al. "A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection." Nature Communications, vol. 11, no. 1, 2020, p. 2251.
Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251.
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., & Bosch, B. J. (2020). A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications, 11(1), 2251. https://doi.org/10.1038/s41467-020-16256-y
Wang C, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020 05 4;11(1):2251. PubMed PMID: 32366817.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A human monoclonal antibody blocking SARS-CoV-2 infection. AU - Wang,Chunyan, AU - Li,Wentao, AU - Drabek,Dubravka, AU - Okba,Nisreen M A, AU - van Haperen,Rien, AU - Osterhaus,Albert D M E, AU - van Kuppeveld,Frank J M, AU - Haagmans,Bart L, AU - Grosveld,Frank, AU - Bosch,Berend-Jan, Y1 - 2020/05/04/ PY - 2020/03/27/received PY - 2020/04/23/accepted PY - 2020/5/6/entrez PY - 2020/5/6/pubmed PY - 2020/5/7/medline SP - 2251 EP - 2251 JF - Nature communications JO - Nat Commun VL - 11 IS - 1 N2 - The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19. SN - 2041-1723 UR - https://www.unboundmedicine.com/medline/citation/32366817/full_citation L2 - http://dx.doi.org/10.1038/s41467-020-16256-y DB - PRIME DP - Unbound Medicine ER -